SCHEMBL10310591

SCHEMBL10310591

CCOC(C)C(=O)NC(C)NC(=O)C(C)N1C(=O)C=CC1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ USP2 O75604 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ GSK3A P49840 1/20 0.33
▸ GSK3B P49841 1/20 0.33
▸ HPGD P15428 2/20 0.33
▸ HTT P42858 2/20 0.33
▸ HSP90AA1 P07900 1/20 0.33
▸ CACNA1B Q00975 1/20 0.33
▸ APBA1 Q02410 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ POLB P06746 1/20 0.32
▸ ACACB O00763 1/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ BLM P54132 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16203709 0.90 KDM4E (0.31) ALDH1A1NPSR1MEN1KMT2AKDM4E
SCHEMBL10310590 0.87 ALDH1A1 (0.37) ALDH1A1NPSR1MEN1KMT2AKDM4E
SCHEMBL327611 0.84 SMN1; SMN2 (0.35) ALDH1A1HSD17B10HTTPOLBACACB
SCHEMBL12505905 0.81 HTT (0.35) NPSR1MEN1KMT2AHTTPOLB
SCHEMBL10310592 0.79 AKT1 (0.34) HSD17B10POLB
SCHEMBL13448309 0.79 POLB (0.35) ALDH1A1NPSR1MEN1KMT2AKDM4E
SCHEMBL13531985 0.79 GSK3A (0.36) ALDH1A1NPSR1MEN1KMT2AGSK3A
SCHEMBL18470777 0.79 GSK3A (0.31) GSK3AGSK3B
SCHEMBL2610530 0.79 POLB (0.36) ALDH1A1KDM4EHTTPOLBCYP1A2
SCHEMBL10037571 0.77 POLB (0.37) ALDH1A1KDM4EHSD17B10HPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180085468-A1 CONJUGATES OF AN IL-2 MOIETY AND A POLYMER NEKTAR THERAPEUTICS 2018-03-29 — — US disclosed
US-8889831-B2 Unit dosage forms of pharmaceutical compositions comprising a polymer-factor VIII polypeptide conjugate NEKTAR THERAPEUTICS (US) 2014-11-18 — — US disclosed
US-20120178692-A1 DOSAGE FORMS OF POLYMER-FACTOR VIII MOIETY CONJUGATES NEKTAR THERAPEUTICS (US) 2012-07-12 — — US disclosed
US-20110171160-A1 POLYMER CONJUGATES OF KISS1 PEPTIDES NEKTAR THERAPEUTICS (US) 2011-07-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110171160-A1 POLYMER CONJUGATES OF KISS1 PEPTIDES KISS1R, PROKR1, NGLY1 ALDH1A1 3897/4885NPSR1 27/4885MEN1 39/4885
US-20180085468-A1 CONJUGATES OF AN IL-2 MOIETY AND A POLYMER IL2, IL2RA, ILF2 ALDH1A1 3489/4885NPSR1 1462/4885MEN1 3695/4885
US-20120178692-A1 DOSAGE FORMS OF POLYMER-FACTOR VIII MOIETY CONJUGATES F8, F9, F13B ALDH1A1 2188/4885NPSR1 3860/4885MEN1 882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback